Rapid Reduction of HbA1c and Weight in Elderly Patient with Type 2 Diabetes (T2D) And Depression by Oral Semaglutide (Rybelsus)

Asploro journal of biomedical and clinical case reports Pub Date : 2022-07-23 DOI:10.36502/2022/asjbccr.6267

H. Bando, Kenji Hayashi, Kyoko Sumitomo, Kazuya Miki, Asami Kamoto

引用次数: 4

Abstract

Background: Oral semaglutide (Rybelsus) has been in focus for type 2 diabetes (T2D). Case Presentation: The patient is a 73-year-old male with T2D treated with metformin, Ipragliflozin, and rosuvastatin. He was diagnosed with depression by the Geriatric depression scale (GDS) with a stable condition by mirtazapine. His diabetic control was exacerbated to HbA1c 8.8% and weight 63.5kg in Feb 2022. Results: He started to take Rybelsus, and then clinical improvement was found as HbA1c 6.9% and weight 57.5kg for 4 months. Discussion: Remarkable effect of HbA1c and weight may be from longer fasting time after post-med, and regular lifestyle from the stable psychosomatic situation.

查看原文本刊更多论文

口服Semagulide（Rybelsus）快速降低老年2型糖尿病（T2D）和抑郁症患者的HbA1c和体重

背景：口服赛马鲁肽（Rybelsus）一直是2型糖尿病（T2D）的焦点。病例介绍：患者为一名73岁的男性，患有T2D，接受二甲双胍、依匹拉利嗪和瑞舒伐他汀治疗。他被老年抑郁症量表（GDS）诊断为抑郁症，服用米氮平病情稳定。2022年2月，他的糖尿病控制恶化至HbA1c 8.8%，体重63.5kg。结果：他开始服用Rybelsus，随后临床改善为HbA1c 6.9%，体重57.5kg，持续4个月。讨论：HbA1c和体重的显著影响可能来自于服药后较长的禁食时间，以及稳定的身心状况带来的规律的生活方式。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Asploro journal of biomedical and clinical case reports

自引率

0.00%

发文量